Objective: This study aimed to analyze cytomegalovirus (CMV) reactivation and its influencing factors in patients with B-lymphocyte malignancy who received chimeric antigen receptor T (CAR-T) cell therapy. Methods: This study retrospectively reviewed patients with B-lymphocyte malignan …
This nonrandomized clinical trial examines whether matched-targeted therapy based on tumor mutation status with a PD-L1 inhibitor is associated with improved overall survival among patients…
Investigators hope to add a treatment option that has the potential to produce superior efficacy vs present ROS1 inhibitors for patients with ROS1+ NSCLC.
NRG1 fusion positivity has gained interest as a treatment target in lung and pancreatic cancer, leading to the FDA approval of zenocutuzumab in December 2024.
Are you an ambitious researcher looking for your next challenge? Do you have a background in economics, econometrics, statistics, epidemiology or health data science? Are…
Access articles from The Lancet Oncology, covering topics that advance clinical practice, challenge the status quo, advocate change in health policy, and tackle issues related…
Jack Khouri, MD, Cleveland Clinic, Cleveland, OH, comments on a study investigating the outcomes of teclistamab treatment in patients with relapsed/refractory multiple myeloma (RRMM) who…
Lynch syndrome (LS) is an autosomal dominant hereditary cancer predisposition syndrome whereby the lifetime risk of developing gastrointestinal and genitourinary cancers rises by to over…
Herbert Loong, Clinical Associate Professor in the Department of Clinical Oncology at the Chinese University of Hong Kong, discusses key sarcoma updates from…
Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care.
